Update information
May 2024: The wording in recommendation 1.1 has been updated to address concerns raised by the clinical community and company that the previously used definition of rapidly evolving severe multiple sclerosis (RES) was overly restrictive. This is because the requirement for 2 MRI scans places significant burden on a limited diagnostic and monitoring resource. The wording has now been changed to better reflect clinical practice.
March 2020: A European Medicines Agency safety review has resulted in a change to alemtuzumab's marketing authorisation indications and warnings and precautions for use. Sections 1 and 2 of the guidance have been updated.
ISBN: 978-1-4731-6146-7